Robin Ji

MS2 @UChiPritzker 👩🏻‍⚕️🩺 previously health policy @UCSF_HVC and public health @UCBerkeley 🐻💙💛

[Marshall Chin @MarshallChinMD]

Here is @UChiPritzker MS2 @RobinZJi presenting her poster on Population Health Management in FQHCs with Dr Monica Peek @SocietyGIM #SGIM25

[Robin Ji @RobinZJi]

Had a blast this weekend presenting my research on optimizing delirium management at the @UCM_HDS Quality & Safety Symposium and then at the @hvpaa #nationalconference hosted by the amazing team at @HopkinsMedicine! First time flying to a conference and first time in Baltimore ☺️

[UChicago Medicine @UChicagoMed]

Meet Jay, a first-year medical student at @UChiPritzker, and one of our musicians in the Sky Lobby through the Healing Arts Program. Have you heard him play on a recent visit?
https://t.co/n0ahvH3Zks

[The University of Chicago @UChicago]

A fresh coat ☃️ ❄️

📸 : Jason Smith

[Alex Everhart @aoeverhart]

"In her final presentation for health policy class at the University of Chicago, first-year medical student Robin Ji informed her classmates that the FDA does not require randomized controlled trials of most medical devices. Her peers’ immediate reaction was disbelief."

[Robin Ji @RobinZJi]

Highly recommend you read this excellent piece on the important findings from @UCSF_HVC’s survey in @Health_Affairs on physician understanding of FDA approvals and implications for policy / med ed.

And some tidbits about my first year at @UChiPritzker if you’re interested 😉.

[Lizzy Lawrence @LizzyLaw_]

NEW: In a recent UCSF national doctor survey, only 17% of physicians felt they understood the FDA’s device approval process. Around 41% felt they understood the drug side.
https://t.co/5JgCf43lIg

[Health Affairs @Health_Affairs]

New article from Sanket Dhruva of @UCSF_HVC and @RFRedberg, @akesselheim, @robinzji finds physicians’ have limited knowledge of Food and Drug Administration (FDA) drug approval processes. Read the full study: https://t.co/rIZLpqrkkn

[Robin Ji @RobinZJi]

Wow. Just watched this talk by @ETSshow a day after getting texts from friends/family in NorCal about smoky air from wildfires. I’d love to get more education about effects of climate change on health and how med students can be involved in the discussion & make a difference.

[Robin Ji @RobinZJi]

This highlights a key opportunity for care improvement in medicine - encouraging (or requiring) the use of high-quality evidence and guidelines when making important clinical decisions, especially if they involve high-risk procedures.

[Robin Ji @RobinZJi]

Our examination of 159 cases from CA's Independent Med Review program found that most decisions to uphold/overturn healthcare coverage denials didn't have evidence cited to support the evaluations, and most didn't align with prof. society recommendations.
https://t.co/G123w1SAGr

[Robin Ji @RobinZJi]

take a read here or dm if you can't get the full article and want me to send it! 🫶https://t.co/hyOXbUndCP

[Robin Ji @RobinZJi]

Most commenters (incl. physicians, hospitals) on Medicare coverage decisions have a financial stake in the game. @CMSGov should ensure this info is known & encourage input from un-conflicted parties.

I learned so much from working on this study and hope to see change soon.

[JAMA @JAMA_current]

Study reviewed public comments for all Medicare National Coverage Determinations between June 2019 and 2022 on select pulmonary and cardiac devices to determine if financial conflicts of interest were disclosed. https://t.co/Uy3pPK6ixd

[Robin Ji @RobinZJi]

How it started …

Officially a @UChiPritzker student 😎

[Robin Ji @RobinZJi]

Such a blessing to be able to spend couple weeks before the start of MS1 visiting my family (some of whom I haven’t seen in 10 yrs) in Beijing, Dalian, and Shanghai! So many of my childhood core memories were made here & with them. 🥺❤️❤️

[Robin Ji @RobinZJi]

Proud to have worked on this study, published this week in CPT.

Lack of transparency ➡️ lack of trust. Seems like most would agree that more/better data is needed before #aducanumab #lecanemab & similar drugs are approved and widely used in AD patients. FDA: take note.

[UCSF Team for High-Value Care @UCSF_HVC]

New survey study in #CPT on physician perspectives of @US_FDA's 2021 accelerated approval of #aducanumab found that 86% of respondents wouldn't prescribe/recommend the drug and 67% lost trust in other drugs approved through the same accelerated pathway.

https://t.co/eE9ADyozNy